Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.
AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.
The company was founded in 1999 and is headquartered in Alachua, Florida.
October 16, 2015
RegMed’s close: wow!
October 15, 2015
Higher open expected. RegMed’s pre-open, the lack of filed Form 4’s provide insight into sector prospects
October 14, 2015
RegMed’s close: opened positive, finished down; there isn’t any conviction behind the buying -how long will this last?
October 14, 2015
Lower open expected; RegMed pre-open, good news, bad news - share prices are undervalued
October 13, 2015
RegMed’s close: Forget doom and gloom, its current sentiment depressing any upside
October 13, 2015
Lower open expected; RegMed pre-open, momentum stocks have broken down
October 12, 2015
RegMed’s close: a quasi-holiday, narrow ranges, indexes and ETFs are spotty – indecision or boredom?
October 12, 2015
Flat to higher open expected; RegMed pre-open, if you’re sitting at the sentiment table pull up a short stool
October 10, 2015
RegMed’s close: I worry as cell and gene therapy scurry for cover
October 9, 2015
Flat to higher open expected; the cell therapy and RegMed sector needs to tackle their most basic insecurity – cash positions!
35 companies, 1 interpreter!
Insight, foresight and recommendation
Applied Genetics Technology Corporations (AGTC) In Q1/16, AGTC has clinical trial timing issues and spending woes – until clinical results are announced which are slow due to enrollments ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.